Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

The Department of War, under the Defense Health Agency, is soliciting quotations for a Uniform Formulary Blanket Purchase Agreement (UF BPA) and an Additional Discount Program Agreement (UF ADP) as part of its federally mandated pharmacy benefits program for the Military Health System. This program ensures cost-effective and clinically appropriate pharmaceutical procurement guided by the Pharmacy and Therapeutics (P&T) Committee’s evaluation of drug classes for the DoW Uniform Formulary. The solicitation, issued on May 7, 2026, requires manufacturers to submit price quotes for specific pharmaceutical agents within designated drug classes under review—namely ADHD stimulant agents and oncological BRAF-MEK inhibitors—with proposals due by June 29, 2026. The scope includes provision of pharmaceuticals to Military Treatment Facilities, the TRICARE Mail Order Pharmacy, and retail pharmacies within the TRICARE network, with pricing submissions required by National Drug Code (NDC-11), package size, and dispensing channel per regulatory and contractual guidelines. The contract is a Blanket Purchase Agreement type, facilitating ongoing pharmaceutical procurement and pricing reconciliation through quarterly invoicing based on TRICARE retail utilization data. The place of contract performance and administration is primarily San Antonio, Texas, where the Pharmacy Contracting Officer conducts oversight. Submission requirements include signed agreements, detailed pricing tables with unit and package prices, and adherence to federal pricing regulations including the Federal Ceiling Price (FCP) rules under 32 CFR 199.21. The contract incorporates clinical evaluations from the P&T Committee for formulary classification and cost sharing categories, ensuring that pricing and product selection align with government mandates for therapeutic equivalence and cost effectiveness. While no explicit FAR clauses beyond commercial contract terms are detailed, adherence to standard commercial acquisition conditions applies. The solicitation does not specify formal inspection or acceptance criteria beyond distribution at Military Treatment Facilities, and no special contract requirements like security clearances or key personnel are identified. Overall, the contract establishes a framework for government-wide pharmaceutical procurement supporting military health benefits with a total estimated value ranging from approximately $5.8 million to $18.5 million, depending on the execution of base quantities and contract options.